

August 7, 1998

Re: Attached Media Release

UTI Inc. signed an agreement with Eastwood Bio-Medical Research Inc. of Vancouver, Canada, to license a herbal treatment for safely controlling blood glucose levels for Type II diabetics. The treatment was developed at the University of Calgary.

Eastwood Bio-Medical have developed the treatment into a product called ELEOTIN® which it is launching today. The attached information will be of interest to medical, alternative medicine business and technology reporters.

UTI's contact for additional information on the product, contact Eastwood Bio-Medical directly. For information on the University of Calgary's role, UTI's contact is Keith Gilchrist, Licensing Associate, telephone 403-270-7027 or email at gilchrik@uti.ca.

Thanks.

Don Morberg Communications Coordinator UTI Inc. 403-270-7027

morberg@uti.ca